Baseline characteristics of stage IV nonsmall cell lung cancer patients and their first-line treatment
| Cisplatin-pemetrexed | Cisplatin-gemcitabine | Carboplatin-pemetrexed | Carboplatin-gemcitabine | Bevacizumab-carboplatin-paclitaxel | Carboplatin-docetaxel | Gefitinib (with EGFR mutation) | Erlotinib (with EGFR mutation) | Other | All treated patients | |
| Subjects | 347 (29) | 214 (18) | 213 (18) | 171 (14) | 73 (6) | 45 (4) | 35 (3) | 24 (2) | 92 (7) | 1214 (100) |
| Age at diagnosis years | 59±9.7 | 63±9.3 | 65±8.8 | 68±8.0 | 62±9.0 | 59±9.4 | 68±11.3 | 68±12.0 | 63±9.3 | 63±9.6 |
| Male | 171 (49) | 127 (59) | 132 (62) | 123 (72) | 35 (48) | 23 (51) | 15 (43) | 6 (25) | 58 (63) | 690 (57) |
| Comorbidities (CCI) | ||||||||||
| 0 | 216 (62) | 111 (52) | 93 (44) | 68 (40) | 46 (63) | 33 (73) | 23 (66) | 16 (67) | 44 (48) | 650 (54) |
| 1 | 76 (22) | 60 (28) | 62 (29) | 51 (30) | 19 (26) | 8 (18) | 8 (23) | 5 (21) | 28 (30) | 317 (26) |
| 2–3 | 50 (14) | 41 (19) | 54 (25) | 50 (29) | 8 (11) | 3 (7) | 3 (9) | 3 (13) | 15 (16) | 227 (19) |
| ≥4 | 5 (1) | 2 (1) | 4 (2) | 2 (1) | 0 | 1 (2) | 1 (3) | 0 | 5 (5) | 20 (2) |
| ECOG PS | ||||||||||
| 0–1 | 300 (87) | 184 (86) | 172 (81) | 137 (80) | 66 (90) | 40 (89) | 31 (89) | 18 (75) | 75 (82) | 1023 (84) |
| ≥2 | 29 (8) | 12 (6) | 34 (16) | 28 (16) | 5 (7) | 4 (9) | 4 (11) | 4 (17) | 16 (17) | 136 (11) |
| Missing | 18 (5) | 18 (8) | 7 (3) | 6 (4) | 2 (3) | 1 (2) | 0 | 2 (8) | 1 (1) | 55 (5) |
| Histology | ||||||||||
| Squamous | 3 (1) | 103 (48) | 1 (1) | 69 (40) | 0 | 4 (9) | 0 | 1 (4) | 13 (14) | 194 (16) |
| Adenocarcinoma | 284 (82) | 68 (32) | 176 (83) | 50 (30) | 61 (84) | 23 (51) | 32 (91) | 19 (79) | 47 (51) | 760 (63) |
| Large cell | 12 (4) | 18 (8) | 19 (9) | 31 (18) | 7 (10) | 9 (20) | 0 | 0 | 17 (19) | 113 (9) |
| Other or not otherwise specified | 48 (14) | 25 (12) | 17 (8) | 21 (12) | 5 (7) | 9 (20) | 3 (9) | 4 (17) | 15 (16) | 147 (12) |
| Year of diagnosis | ||||||||||
| 2008 | 12 (4) | 49 (23) | 2 (1) | 25 (15) | 1 (1) | 19 (42) | 0 | 0 | 15 (16) | 123 (10) |
| 2009 | 46 (3) | 34 (16) | 15 (7) | 31 (8) | 0 | 7 (16) | 1 (3) | 1 (4) | 15 (16) | 150 (12) |
| 2010 | 42 (12) | 40 (19) | 36 (17) | 15 (9) | 0 | 10 (22) | 9 (26) | 2 (8) | 18 (20) | 172 (14) |
| 2011 | 62 (18) | 22 (10) | 30 (14) | 21 (12) | 24 (33) | 8 (18) | 3 (9) | 3 (13) | 10 (11) | 183 (15) |
| 2012 | 63 (18) | 18 (8) | 45 (21) | 26 (15) | 22 (30) | 1 (2) | 5 (14) | 4 (17) | 11 (12) | 195 (16) |
| 2013 | 65 (19) | 26 (12) | 47 (22) | 29 (17) | 9 (12) | 0 | 12 (34) | 5 (21) | 6 (7) | 199 (16) |
| 2014 | 57 (16) | 25 (12) | 38 (18) | 24 (14) | 17 (23) | 0 | 5 (14) | 9 (38) | 17 (19) | 192 (16) |
Data are presented as n (%) or median±sd. EGFR: epidermal growth factor receptor; CCI: Charlson comorbidity index; ECOG PS: Eastern Cooperative Oncology Group performance status.